Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

somerset therapeutics, llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg (base)/ml and haloperidol decanoate injection, 100 mg (base)/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg /ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol, usp as the active medication, contraindications, warnings, and additional information are those of haloperidol, usp, modified only to reflect the prolonged action.   haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies).

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

teva parenteral medicines, inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurolog

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

cardinal health - haloperidol lactate (unii: 6387s86pk3) (haloperidol - unii:j6292f8l3d) - haloperidol injection, usp is indicated for use in the treatment of schizophrenia. haloperidol injection, usp is indicated for the control of tics and vocal utterances of tourette's disorder. haloperidol injection is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

major pharmaceuticals - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection is indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection are attributed to haloperidol as the active medication,contraindications , warnings , and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ).

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol tablets are indicated for use in the management of manifestations of psychotic disorders. haloperidol tablets are indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol tablets are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol tablets are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol tablets should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol tablets are contraindicated in severe toxic central nervous system depression or comatose states from any caus

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol is indicated for use in the management of manifestations of psychotic disorders. haloperidol is indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this d

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection is indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

zydus lifesciences limited - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection is indicated for the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodi

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

method pharmaceuticals, llc - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol tablets, usp are indicated for use in the management of manifestations of psychotic disorders. haloperidol tablets, usp are indicated for the control of tics and vocal utterances of tourette’s disorder in children and adults. haloperidol tablets, usp are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). haloperidol tablets, usp are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. haloperidol tablets, usp should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. haloperidol tablets, usp are contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson’s disease.